Silo Pharma Files 8-K
Ticker: SILO · Form: 8-K · Filed: Jun 4, 2024 · CIK: 1514183
| Field | Detail |
|---|---|
| Company | Silo Pharma, Inc. (SILO) |
| Form Type | 8-K |
| Filed Date | Jun 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
Silo Pharma filed an 8-K on June 4th, updating corporate info.
AI Summary
Silo Pharma, Inc. filed an 8-K on June 4, 2024, reporting other events and financial statements. The company, formerly known as Uppercut Brands, Inc., Point Capital, Inc., and Gold Swap Inc., is incorporated in Nevada and headquartered in Sarasota, Florida.
Why It Matters
This filing provides an update on Silo Pharma's corporate activities and financial reporting, which is important for investors to understand the company's current status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.
Key Players & Entities
- Silo Pharma, Inc. (company) — Registrant
- June 4, 2024 (date) — Date of earliest event reported
- Uppercut Brands, Inc. (company) — Former company name
- Point Capital, Inc. (company) — Former company name
- Gold Swap Inc (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
- Sarasota, FL (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Silo Pharma, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of June 4, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on June 4, 2024.
What are some of the former names of Silo Pharma, Inc. mentioned in the filing?
The filing mentions that Silo Pharma, Inc. was formerly known as Uppercut Brands, Inc., Point Capital, Inc., and Gold Swap Inc.
In which state is Silo Pharma, Inc. incorporated?
Silo Pharma, Inc. is incorporated in Nevada.
What is the address of Silo Pharma, Inc.'s principal executive offices?
The address of Silo Pharma, Inc.'s principal executive offices is 677 N. Washington Boulevard, Sarasota, FL 34236.
Filing Stats: 430 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-06-04 16:05:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SILO The Nasdaq Stock Mar
Filing Documents
- ea0207247-8k_silo.htm (8-K) — 25KB
- ea020724701ex99-1_silo.htm (EX-99.1) — 10KB
- 0001213900-24-049658.txt ( ) — 206KB
- silo-20240604.xsd (EX-101.SCH) — 3KB
- silo-20240604_lab.xml (EX-101.LAB) — 33KB
- silo-20240604_pre.xml (EX-101.PRE) — 22KB
- ea0207247-8k_silo_htm.xml (XML) — 3KB
01 – Other Events
Item 8.01 – Other Events On June 3, 2024,Silo Pharma Inc. (the "Company") issued a press release announcing the submission its Pre-Investigational New Drug Application to FDA for SPC-15. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated June 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -1-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILO PHARMA, INC. Date: June 4, 2024 By: /s/ Eric Weisblum Eric Weisblum Chief Executive Officer -2-